Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate
treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a
continuous daily regimen (once per day) for one year.